Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

The Role of Kras and Canonical Wnt Pathways in Biliary Tract Cancers

Trending

March 1, 2023
In a recent Oncotarget editorial, researchers discuss Kras and the canonical Wnt pathway in biliary tract cancers, and potential theraputic strategies using these targets. continue reading »

Oncotarget | WNT-pathway Medulloblastoma: What Constitutes Low-risk and How Low Can One Go?

News

February 27, 2023
PRESS RELEASE: On February 7, 2023, a new research perspective was published in Oncotarget, entitled, “WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?” continue reading »

Oncotarget | Oncogenic Driver FGFR3-TACC3 Requires 5 Coiled-coil Heptads for Activation and Disulfide Bonds for Stability

News

February 23, 2023
PRESS RELEASE: On February 11, 2023, a new research paper was published in Oncotarget, entitled, “Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.” continue reading »

Oncotarget’s Top 10 Papers in 2022 (Crossref Data)

Oncotarget

February 21, 2023
Read Crossref’s Top 10 Oncotarget DOIs in 2022. continue reading »

Oncotarget | Extreme Phenotype Approach Identifies Rare ATR Variants as Potential Male Breast Cancer Susceptibility Alleles

News

February 21, 2023
PRESS RELEASE: On February 7, 2023, a new research paper was published in Oncotarget, entitled, “The ‘extreme phenotype approach’ applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles.” continue reading »